ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 12% – Should You Sell?

Posted by Geri Gentry on Nov 9th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) shares fell 12% during mid-day trading on Monday. The company traded as low as $20.62 and last traded at $18.6830. Approximately 1,716,763 shares traded hands during trading, a decline of 2% from the average session volume of 1,750,585 shares. The stock had previously closed at $21.23.

Wall Street Analysts Forecast Growth

ACAD has been the subject of several analyst reports. Weiss Ratings upgraded ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, August 12th. HC Wainwright decreased their price target on ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research report on Friday, September 25th. William Blair set a $33.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, September 28th. Bank of America restated a “buy” rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, UBS Group cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $49.00 to $23.00 in a research note on Tuesday, October 13th. Thirteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.55.

Read Our Latest Stock Analysis on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Stock Performance

The company has a market cap of $3.21 billion, a P/E ratio of 8.84 and a beta of 0.87. The stock has a 50-day moving average of $22.86 and a two-hundred day moving average of $23.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.11. The business had revenue of $342.30 million for the quarter, compared to analysts’ expectations of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The business’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the business earned $0.42 earnings per share. As a group, sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.74 EPS for the current fiscal year.

Insider Activity

In related news, EVP Mark Schneyer sold 3,321 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president owned 71,322 shares of the company’s stock, valued at approximately $1,489,203.36. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Nykredit A S bought a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at about $38,000. Integrated Wealth Concepts LLC bought a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $50,000. Global Retirement Partners LLC bought a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $64,000. GAMMA Investing LLC lifted its stake in shares of ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 402 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 707.6% in the 3rd quarter. Sterling Capital Management LLC now owns 4,337 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 3,800 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations.

Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.